RSRoss Sadler

Ross Sadler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ross Sadler has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determinants of durable humoral and T cell immunity in myeloma patients following COVID‐19 vaccination

    by Clement Twumasi, Sally Moore, Ross Sadler, Sally Jeans, Sherin Varghese, Alison Turner, Gaurav Agarwal, Jemma Larham, Nathanael Gray, Oluremi Carty, et al.

    Objective: To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma.Methods: This is a prospective, observational study utilising the platform. Participants reported their second and third COVID-19 vaccination dates. Myeloma patients had an Anti-S antibody level sample taken at least 21 days after their second vaccination and a repeat sample before their third vaccination.Results: 60 patients provided samples at least 3 weeks (median 57.5 days) after their second vaccination and before their third vaccination (median 176.0 days after second vaccine dose). Low Anti-S antibody levels (<50 IU/mL) doubled during this interval (p = .023) and, in the 47 participants with T-spot data, there was a 25% increase negative T-spot tests (p = .008). Low anti-S antibody levels prior to the third vaccination were predicted by lower Anti-S antibody level and negative T-spot status after the second vaccine. Independent determinants of a negative T-spot included increasing age, previous COVID infection, high CD4 count and lower percentage change in Anti-S antibody levels.Conclusions: Negative T-spot results predict low Anti-S antibody levels (<50 IU/mL) following a second COVID-19 vaccination and a number of biomarkers predict T cell responses in myeloma patients.


  • Open Access

    Impacts of helmet law on the changes in potential years of life lost due to traffic injury: a multiple-province evaluation in Vietnam

    by Dung Phung, Ha Trong Nguyen, Cordia Chu, Ross Sadler, Anh Mai Luong, Huyen Thi Nguyen, Tuan Cong Pham, Cunrui Huang

    Introduction: This study aimed to evaluate the impact of the helmet law on the changes in potential years of life lost (PYLL) due to traffic mortality and to examine modification effects of socioeconomic factors on the impacts in Vietnam. Methods: We applied an interrupted time series design using the Bayesian framework to estimate the impact of the law at the provincial level. Then, we used random effects meta-analysis to estimate the impact of the law at the country level and to examine the modification effects of socioeconomic factors. Results: The results indicate that the impacts varied among the provinces. These impacts could be classified by four main groups comprising positive impact, and positive impact without sustainability, possible positive impact, negative or inconsistent impact. For the country-level impact, the results reveal a significantly consistent change in monthly PYLLs at the level of 18 per 100 000 persons, and the post-trend was stable without significant change. The results of meta-regression show that 1 unit increase in the population density (persons/km2), migration rate (%) and income (×1000 dong) are non-significantly associated with increases of PYLLs at 1.3, 27 and 27 per 100 000 person-months, respectively, whereas 1% increase in literacy associated with a decrease of PYLL at 44 per 100 000 person-months. Discussion: Further studies should be warranted to provide a comprehensive evaluation of the law implementation, including its acceptability, adoption, appropriateness, feasibility, cost-effectiveness and sustainability.


  • Open Access

    Towards a more complete understanding of the occurrence and toxicities of the cylindrospermopsins

    by Ross Sadler

    The existence of a number of cylindrospermopsin analogs has been confirmed by several authors. These cylindrospermopsin analogs were formerly seen as minor constituents, with normal cylindrospermopsin always being the dominant form. However, it is now clear that the cylindrospermopsin analogs are the major species produced by certain organisms, the production being enhanced, at least in some cases, under specific physiological conditions. Presently, relatively little information is available concerning the properties, physiology of occurrence and toxicity of these molecules. The existing literature pertaining to these aspects is reviewed with respect to known cylindrospermopsin analogs. The biosynthesis of the cylindrospermopsins is discussed and the previously established pathway has been modified to take account of the production of the known cylindrospermopsin forms. The anomalies in terms of in-vivo toxicity of 7-deoxy-cylindrospermopsin are reported, along with further attempts to rationalize the situation. We also discuss reasons for the apparently similar toxicity of 7-deoxy-cylindrospermopsin and cylindrospermopsin to cell cultures in vitro. It is hypothesized that the similarity of cylindrospermopsin intoxication to nonalcoholic fatty liver disease may argue for these cyanotoxins to exert their effects via a lysosomal pathway.